Literature DB >> 9159131

Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor.

M Zhang1, D Magit, R Sager.   

Abstract

Prostate cancer is the most common cancer in men. The molecular mechanisms leading to its development are poorly understood. Maspin is a tumor-suppressing serpin expressed in normal breast and prostate epithelium. We have found that expression of maspin in normal and carcinoma-derived prostate epithelial cells is differentially regulated at the transcriptional level. We have identified two different kinds of cis elements, Ets and hormonal responsive element (HRE), in the maspin promoter. The Ets element is active in regulating maspin expression in normal prostate epithelial cells but inactive in tumor cells. The HRE site is a negative element that is active in both cell types. This negative DNA sequence can repress a heterologous promoter recognized by the androgen receptor. We conclude that expression of maspin is under the influence of both a positive Ets and a negative HRE element. Loss of maspin expression during tumor progression apparently results from both the absence of transactivation through the Ets element and the presence of transcription repression through the negative HRE element recognized by androgen receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159131      PMCID: PMC20837          DOI: 10.1073/pnas.94.11.5673

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  Gene regulation by steroid hormones.

Authors:  M Beato
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

2.  Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin.

Authors:  M Zhang; N Maass; D Magit; R Sager
Journal:  Cell Growth Differ       Date:  1997-02

3.  Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene.

Authors:  D D Sakai; S Helms; J Carlstedt-Duke; J A Gustafsson; F M Rottman; K R Yamamoto
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

Review 4.  A critical review of the concept of total androgen ablation in the treatment of prostate cancer.

Authors:  H Schulze; J T Isaacs; D S Coffey
Journal:  Prog Clin Biol Res       Date:  1987

5.  ras gene mutations in human prostate cancer.

Authors:  B S Carter; J I Epstein; W B Isaacs
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

6.  Oncogenic potential of bcl-2 demonstrated by gene transfer.

Authors:  J C Reed; M Cuddy; T Slabiak; C M Croce; P C Nowell
Journal:  Nature       Date:  1988-11-17       Impact factor: 49.962

7.  Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone.

Authors:  C Jonat; H J Rahmsdorf; K K Park; A C Cato; S Gebel; H Ponta; P Herrlich
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Allelic loss of chromosomes 16q and 10q in human prostate cancer.

Authors:  B S Carter; C M Ewing; W S Ward; B F Treiger; T W Aalders; J A Schalken; J I Epstein; W B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

10.  The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites.

Authors:  A Gutman; B Wasylyk
Journal:  EMBO J       Date:  1990-07       Impact factor: 11.598

View more
  24 in total

1.  Aberrant methylation of the maspin promoter is an early event in human breast cancer.

Authors:  Bernard W Futscher; Megan M O'Meara; Christina J Kim; Margaret A Rennels; Di Lu; Lynn M Gruman; Richard E B Seftor; Mary J C Hendrix; Frederick E Domann
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

2.  Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.

Authors:  Shizhen Emily Wang; Archana Narasanna; Corbin W Whitell; Frederick Y Wu; David B Friedman; Carlos L Arteaga
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

3.  A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression.

Authors:  Wei Qi; Hong Wu; Lin Yang; Douglas D Boyd; Zhengxin Wang
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

4.  Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.

Authors:  M Margarida Bernardo; Yonghong Meng; Jaron Lockett; Gregory Dyson; Alan Dombkowski; Alexander Kaplun; Xiaohua Li; Shuping Yin; Sijana Dzinic; Mary Olive; Ivory Dean; David Krass; Kamiar Moin; R Daniel Bonfil; Michael Cher; Wael Sakr; Shijie Sheng
Journal:  Genes Cancer       Date:  2011-11

Review 5.  Maspin: the new frontier.

Authors:  Zhila Khalkhali-Ellis
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

Review 6.  Genomic and biochemical insights into the specificity of ETS transcription factors.

Authors:  Peter C Hollenhorst; Lawrence P McIntosh; Barbara J Graves
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

7.  Maspin expression in carcinoma ex pleomorphic adenoma.

Authors:  M T Martins; A Altemani; L Freitas; V C Araújo
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

8.  Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts.

Authors:  Mark A Horswill; Malathi Narayan; Debra J Warejcka; Lisa A Cirillo; Sally S Twining
Journal:  Exp Eye Res       Date:  2008-01-12       Impact factor: 3.467

9.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.

Authors:  Scott M Dehm; Lucy J Schmidt; Hannelore V Heemers; Robert L Vessella; Donald J Tindall
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

10.  Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.

Authors:  Adriana S Beltran; Xueguang Sun; Paul M Lizardi; Pilar Blancafort
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.